Quidel Corporation

Quidel Corporation

Quidel Corporation was founded in 1979 by Kenneth Buechler in San Diego as a developer of rapid diagnostic tests. The company went public in 1985 and has since expanded through organic growth and acquisitions, including the 2022 merger with Ortho Clinical Diagnostics in a $5.1B deal (per public record, 2022). Wealth origin is tied to founder equity and public-market value, not a single-family fortune. Quidel's strategy centers on point-of-care diagnostics across respiratory illness, infectious disease, and women's health. The company manufactures and sells immunoassay and molecular testing platforms — including the Sofia and Lyra product lines — to hospitals, clinics, and laboratories globally. Geographically, Quidel has a presence in North America, Europe, and Asia, with its diagnostic kits distributed through commercial partnerships and direct sales. As of 2026, Quidel employs over 5,000 people and operates R&D and manufacturing facilities in San Diego and Rochester, New York. The firm has not disclosed an AUM or deployment figure; it functions as a publicly traded corporation with a market capitalization of approximately $3.5B (per Yahoo Finance, 2026). No distinct family office, philanthropic foundation, or adjacent vehicle has been publicly reported separate from the corporate entity. The structural differentiator for Quidel is its public-company governance and scale: it is not a family office but a publicly held diagnostics firm. This structure provides access to capital markets and a broad shareholder base, distinct from the closed, private-equity-like posture of most family offices. Succession and leadership transitions follow corporate governance norms rather than family trust structures.